|
12 Feb 2021 |
Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
|
|
12 Feb 2021 |
Amicus’ AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPEL Study
|
|
10 Feb 2021 |
Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021
|
|
10 Feb 2021 |
BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition
|
|
10 Feb 2021 |
Affibody and Inmagene announce IND Clearance for Izokibep (ABY-035) for the treatment of Ankylosing Spondylitis
|
|
09 Feb 2021 |
Brooklyn ImmunoTherapeutics Announces Phase 2 Trial of IRX-2 in Combination with Pembrolizumab and Chemotherapy in Triple Negative Breast Cancer
|
|
08 Feb 2021 |
Entera Bio Initiates New Research Program For Oral GLP-2
|
|
08 Feb 2021 |
Onco-immunology Company Pan Cancer T Launched as Spin-off from Erasmus Medical Center
|
|
04 Feb 2021 |
Molecular Partners and Novartis COVID-19 Antiviral Candidate, Ensovibep, Maintains Binding and Neutralization of New Viral Variants in vitro
|
|
04 Feb 2021 |
Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes
|
|
03 Feb 2021 |
VectivBio Announces First Patient Dosed in Pivotal Phase 3 Trial of Apraglutide for the Treatment of Short Bowel Syndrome
|
|
03 Feb 2021 |
4D pharma presents update on oncology program
|
|
01 Feb 2021 |
Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
|
|
01 Feb 2021 |
Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development Program
|
|
01 Feb 2021 |
Gemini Therapeutics Announces Initiation of GEM103 Phase 2a Study as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy
|
|
01 Feb 2021 |
Ovoca Bio Announces First Patient Enrolled in Phase II Dose Ranging Study Assessing BP-101 for HSDD
|
|
29 Jan 2021 |
Novo Nordisk receives positive opinion from the European regulatory authorities for once-weekly Sogroya® (somapacitan) for the treatment of adult growth hormone deficiency
|
|
28 Jan 2021 |
PhaseBio Presents Data from Phase 1b/2a Trial of Pemziviptadil for the Treatment of Pulmonary Arterial Hypertension at 15th Pulmonary Vascular Research Institute Virtual World Congress
|
|
24 Jan 2021 |
Announcing Marketing Approval for Hunterase ICV Injection 15 mg, the World’s First Enzyme Replacement Therapy for Mucopolysaccharidosis Type II (Hunter Syndrome) Administered by ICV Injection
|
|
24 Jan 2021 |
FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis
|
|
21 Jan 2021 |
Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
|
|
21 Jan 2021 |
INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer’s Disease in Phase 1b Trial
|
|
20 Jan 2021 |
Merck Announces Update on the INTR@PID Clinical Program Including Lung 037 Study
|
|
10 Jan 2021 |
Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201
|
|
07 Jan 2021 |
PharmaEssentia Initiates Pivotal Trial of Ropeginterferon alfa-2b to Treat Essential Thrombocythemia
|
